| 05/15/2026 5:01 AM | Fortress Biotech (1429260) Subject HIGHBRIDGE CAPITAL MANAGEMENT LLC (919185) Filed by | Form SCHEDULE 13G/A | |
| 05/14/2026 3:31 PM | Fortress Biotech (1429260) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 04/28/2026 3:15 PM | Fortress Biotech (1429260) Filer | Form DEF 14A | |
| 04/28/2026 3:17 PM | Fortress Biotech (1429260) Filer | Form DEFA14A | |
| 03/31/2026 4:05 PM | Fortress Biotech (1429260) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/20/2026 3:16 PM | Fortress Biotech (1429260) Subject ROSENWALD LINDSAY A MD (941841) Filed by | Form SCHEDULE 13D/A | |
| 03/20/2026 3:05 PM | Fortress Biotech (1429260) Issuer WEISS MICHAEL S (1038977) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/20/2026 3:05 PM | Fortress Biotech (1429260) Issuer ROSENWALD LINDSAY A MD (941841) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/23/2026 7:35 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/13/2026 8:19 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/06/2026 3:05 PM | AVENUE THERAPEUTICS, INC. (1644963) Issuer Fortress Biotech (1429260) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for FBIOP and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.
|
| 01/05/2026 4:00 PM | Fortress Biotech (1429260) Filed by MUSTANG BIO, INC. (1680048) Subject | Form SCHEDULE 13D/A | |
| 12/17/2025 11:15 PM | Fortress Biotech (1429260) Filer | Form EFFECT | |
| 12/15/2025 3:33 PM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/15/2025 7:30 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/17/2025 6:30 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/14/2025 7:35 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/14/2025 7:46 AM | Fortress Biotech (1429260) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/01/2025 3:05 PM | Fortress Biotech (1429260) Reporting MUSTANG BIO, INC. (1680048) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2025 3:11 PM | Fortress Biotech (1429260) Filed by MUSTANG BIO, INC. (1680048) Subject | Form SCHEDULE 13D/A | |
| 10/01/2025 7:45 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/14/2025 3:10 PM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/16/2025 4:25 PM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/23/2025 7:55 AM | Fortress Biotech (1429260) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/03/2025 5:46 PM | Checkpoint Therapeutics, Inc. (1651407) Subject Fortress Biotech (1429260) Filed by | Form SCHEDULE 13D/A | |
| 06/03/2025 5:34 PM | Checkpoint Therapeutics, Inc. (1651407) Issuer Fortress Biotech (1429260) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |